Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

Next Previous
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VE 202 (Primary) ; Vancomycin
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms COLLECTiVE202
  • Sponsors Vedanta Biosciences

    • Most Recent Events

    • 23 Jul 2024 According to a Vedanta Biosciences media release, company announced three appointments to its leadership team. Christof Marre, a seasoned biopharma marketing leader, joins the company as Senior Vice President and Head of Commercial, appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303
    • 04 Oct 2023 According to a PureTech Health media release, first patient has been dosed in this trial.
    • 22 May 2023 Planned End Date changed from 1 Feb 2025 to 10 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top